medRxiv
August 14, 2026
Annette M Braxton, Christina Driver, Daniel F. Hermens et al.
preprint
Abstract Major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are prevalent, chronic, and disabling mental health conditions which are difficult to treat. Ketamine has demonstrated effect for improving depression and PTSD symptoms independently but reports often overlook focused comorbid improvement of these symptoms within individuals. To address this, we assessed...
medRxiv Preprint Server
March 2, 2025
Bonnie L. Quigley, Emerald Orr, Sophie Kafka et al.
preprint
Ketamine has been investigated as a treatment alternative for PTSD for the last 20 years, yet there have been virtually no reports of biological changes or biomarker characterisation related to treatment. To address this significant gap, this study analysed blood samples from 25 participants with PTSD who took part in an open-label 6-week trial of low dose oral ketamine treatment. Serum and...
medRxiv Preprint Server
November 26, 2024
Bonnie L. Quigley, Adem T. Can, Megan Dutton et al.
1 citation
preprint
Ketamine is being actively investigated as a rapid-acting treatment for many conditions with a stress-related psychopathology, including post-traumatic stress disorder (PTSD). The majority of studies regarding ketamine treatment for PTSD to date (including open-label and randomised control trials) have focused on intravenous (IV) ketamine administration. This administration route has...
Brain and Behavior
November 1, 2024
Jules S Mitchell, Toomas E Anijärv, Adem T. Can et al.
Subanesthetic doses of ketamine are a promising novel treatment for suicidality; however, the evidence for predictive biomarkers is sparse. Recently, measures of complexity, including Lempel-Ziv complexity (LZC) and multiscale entropy (MSE), have been implicated in ketamine's therapeutic action. We evaluated electroencephalogram (EEG)-derived LZC and MSE differences between responders and...
European Archives of Psychiatry and Clinical Neuroscience
May 21, 2024
Zack Y Shan, Adem T. Can, Abdalla Z Mohamed et al.
3 citations
The underlying brain mechanisms of ketamine in treating chronic suicidality and the characteristics of patients who will benefit from ketamine treatment remain unclear. To address these gaps, we investigated temporal variations of brain functional synchronisation in patients with suicidality treated with ketamine in a 6-week open-label oral ketamine trial. The trial's primary endpoint was the...
Psychopharmacology
December 1, 2023
Megan Dutton, Adem T. Can, Jim Lagopoulos et al.
Abstract Ketamine has received considerable attention for its rapid and robust antidepressant response over the past decade. Current evidence, in clinical populations, predominantly relates to parenterally administered ketamine, which is reported to produce significant undesirable side effects, with additional concerns regarding long-term safety and abuse potential. Attempts to produce a...
Clinical Case Reports
December 1, 2022
Adem T. Can, Daniel F. Hermens, Jim Lagopoulos
6 citations
Abstract Numerous studies have demonstrated that low‐dose subanesthetic intravenous ketamine infusion treatment leads to rapid improvement of treatment‐resistant depression. The following case report describes the use of a very low‐dose subcutaneous ketamine as a form of maintenance in a patient with severe treatment‐resistant depression using a retrospective chart review.
Progress in Neuro-Psychopharmacology and Biological Psychiatry
July 1, 2022
Christina Driver, Timothy N. W. Jackson, Jim Lagopoulos et al.
The so-called "psychedelic renaissance" has stimulated expanded interest in several classes of drugs that appear to possess transdiagnostic effects in the treatment of mental health disorders, specifically. N-methyl-d-aspartate receptor (NMDAR) antagonists are one such class with diverse therapeutic potential. NMDARs mediate excitatory postsynaptic signalling in the central nervous system (CNS)...
Brain Imaging and Behavior
May 18, 2022
Michelle Kennedy, Abdalla Z Mohamed, Paul Schwenn et al.
Mindfulness training has been associated with improved attention and affect regulation in preadolescent children with anxiety related attention impairments, however little is known about the underlying neurobiology. This study sought to investigate the impact of mindfulness training on functional connectivity of attention and limbic brain networks in pre-adolescents. A total of 47 children with...
Psychopharmacology
December 2010
Robert A Battisti, Steven Roodenrys, Stuart J Johnstone et al.
Chronic cannabis use has been related to deficits in cognition (particularly memory) and the normal functioning of brain structures sensitive to cannabinoids. There is increasing evidence that conflict monitoring and resolution processes (i.e. the ability to detect and respond to change) may be affected. This study examined the ability to inhibit an automatic reading response in order to...
Psychopharmacology
May 2010
Robert A Battisti, Steven Roodenrys, Stuart J Johnstone et al.
The endogenous cannabinoid system is sensitive to the introduction of exogenous cannabinoids such as delta-9-tetrahydrocannabinol, which are known to impact upon memory functioning. We sought to examine the impact of chronic cannabis use upon memory-related brain function via examination of the subsequent memory effect (SME) of the event-related potential (ERP). The SME is predictive of recall...